On 20th of November 2014 Cyntegrity presents the solutions for effective risk-based monitoring and clinical data quality on the conference Pharma forum.
The Pharma Forum occurs this year in the capital of the German state of Saarland in Saarbruecken on the 20th of November 2014. This conference was organized in 2003 for the first time. Since that time this event has established itself as a profound intellectual communication platform, which offers a bridge between research organizations and industry. Joint projects between Big Pharma and young companies in research-related area is the main benefit of all participants.
The CEO of Cyntegrity Artem Andrianov presents this time on the Pharma Forum successful case-studies of the Risk-based monitoring and speaks about the advantage of this approach for the industry.
We would like to invite everybody who has an interest in this topic to Saarbruecken!
Please see the program here: http://www.pharmaforum-sw.de/1399.htm
Information about speakers: http://www.pharmaforum-sw.de/1400.htm
On 20th of November 2014 Cyntegrity presents the solutions for effective risk-based monitoring and clinical data quality on the conference Pharma forum.
The Pharma Forum occurs this year in the capital of the German state of Saarland in Saarbruecken on the 20th of November 2014. This conference was organized in 2003 for the first time. Since that time this event has established itself as a profound intellectual communication platform, which offers a bridge between research organizations and industry. Joint projects between Big Pharma and young companies in research-related area is the main benefit of all participants.
The CEO of Cyntegrity Artem Andrianov presents this time on the Pharma Forum successful case-studies of the Risk-based monitoring and speaks about the advantage of this approach for the industry.
We would like to invite everybody who has an interest in this topic to Saarbruecken!
Please see the program here: http://www.pharmaforum-sw.de/1399.htm
Information about speakers: http://www.pharmaforum-sw.de/1400.htm
